To reveal putative immunopathogenic roles of T cells in severe COVID-19, we performed mass cytometry of whole blood samples from mild and severe COVID-19 patients during the acute and convalescent phase, alongside patients with other acute respiratory infections (Flu-like illness, FLI), as well as patients chronically infected by human immunodeficiency virus (HIV) or hepatitis B (HBV) and controls.